Introduction

Background

Pemphigus is derived from the Greek word *pemphix* meaning bubble or blister. Pemphigus describes a group of chronic bullous diseases, originally named by Wichman in 1791. The term pemphigus once included most bullous eruptions of the skin, but diagnostic tests have improved, and bullous diseases have been reclassified.

The term pemphigus refers to a group of autoimmune blistering diseases of the skin and mucous membranes characterized histologically by intraepidermal blister and immunopathologically by the finding of in vivo bound and circulating immunoglobulin G (IgG) antibody directed against the cell surface of keratinocytes. The 3 primary subsets of pemphigus include pemphigus vulgaris (PV), pemphigus foliaceus, and paraneoplastic pemphigus. Each type of pemphigus has distinct clinical and immunopathologic features. PV accounts for approximately 70% of pemphigus cases.

Pathophysiology

PV is an autoimmune, intraepithelial, blistering disease affecting the skin and mucous membranes and is mediated by circulating autoantibodies directed against keratinocyte cell surfaces. In 1964, autoantibodies against keratinocyte surfaces were described in patients with pemphigus. Clinical and experimental observations indicate that the circulating autoantibodies are pathogenic. An immunogenetic predisposition is well established.

Blisters in PV are associated with the binding of IgG autoantibodies to keratinocyte cell surface molecules. These intercellular or PV antibodies bind to keratinocyte desmosomes and to desmosome-free areas of the keratinocyte cell membrane. The binding of autoantibodies results in a loss of cell-cell adhesion, a process termed acantholysis. The antibody alone is capable of causing blistering without complement or inflammatory cells.

PV antigen: Intercellular adhesion in the epidermis involves several keratinocyte cell surface molecules. Pemphigus antibody binds to keratinocyte cell surface molecules desmoglein 1 and desmoglein 3. The binding of antibody to desmoglein may have a direct effect on desmosomal adherens or may trigger a cellular process that results in acantholysis. Antibodies specific for nondesmosomal antigens also have been described in the sera of patients with PV; however, the role of these antigens in the pathogenesis of disease is not known.
Antibodies: Patients with active disease have circulating and tissue-bound autoantibodies of both the immunoglobulin G1 (IgG1) and immunoglobulin G4 (IgG4) subclasses. Disease activity correlates with antibody titer in most patients.

Complement: Pemphigus antibody fixes components of complement to the surface of epidermal cells. Antibody binding may activate complement with the release of inflammatory mediators and recruitment of activated T cells.

**Frequency**

**United States**

PV is uncommon, and the exact incidence and prevalence depends on the population studied.

**International**

PV has been reported to occur worldwide. PV incidence varies from 0.5-3.2 cases per 100,000. PV incidence is increased in patients of Ashkenazi Jewish descent and those of Mediterranean origin.

**Mortality/Morbidity**

PV is a potentially life-threatening autoimmune mucocutaneous disease with a mortality rate of approximately 5-15%. Complications secondary to the use of high-dose corticosteroids contribute to the mortality rate. Morbidity and mortality are related to the extent of disease, the maximum dose of systemic steroids required to induce remission, and the presence of other diseases. Prognosis is worse in patients with extensive disease and in older patients.

- PV involves mucosa in 50-70% of patients. This may limit oral intake secondary to dysphagia. Blistering
Introduction

Background

Pemphigus is derived from the Greek word pemphix meaning bubble or blister. Pemphigus describes a group of chronic bullous diseases, originally named by Wichman in 1791. The term pemphigus once included most bullous eruptions of the skin, but diagnostic tests have improved, and bullous diseases have been reclassified.

The term pemphigus refers to a group of autoimmune blistering diseases of the skin and mucous membranes characterized histologically by intraepidermal blister and immunopathologically by the finding of in vivo bound and circulating immunoglobulin G (IgG) antibody directed against the cell surface of keratinocytes. The 3 primary subsets of pemphigus include pemphigus vulgaris (PV), pemphigus foliaceus, and paraneoplastic pemphigus. Each type of pemphigus has distinct clinical and immunopathologic features. PV accounts for approximately 70% of pemphigus cases.

Pathophysiology

PV is an autoimmune, intraepithelial, blistering disease affecting the skin and mucous membranes and is mediated by circulating autoantibodies directed against keratinocyte cell surfaces. In 1964, autoantibodies against keratinocyte surfaces were described in patients with pemphigus. Clinical and experimental observations indicate that the circulating autoantibodies are pathogenic. An immunogenetic predisposition is well established.

Blisters in PV are associated with the binding of IgG autoantibodies to keratinocyte cell surface molecules. These intercellular or PV antibodies bind to keratinocyte desmosomes and to desmosome-free areas of the keratinocyte cell membrane. The binding of autoantibodies results in a loss of cell-cell adhesion, a process termed acantholysis. The antibody alone is capable of causing blistering without complement or inflammatory cells.

PV antigen: Intercellular adhesion in the epidermis involves several keratinocyte cell surface molecules. Pemphigus antibody binds to keratinocyte cell surface molecules desmoglein 1 and desmoglein 3. The binding of antibody to desmoglein may have a direct effect on desmosomal adherens or may trigger a cellular process that results in acantholysis. Antibodies specific for nondesmosomal antigens also have been described in the sera of patients with PV; however, the role of these antigens in the pathogenesis of disease is not known.

Antibodies: Patients with active disease have circulating and tissue-bound autoantibodies of both the immunoglobulin G1 (IgG1) and immunoglobulin G4 (IgG4) subclasses. Disease activity correlates with antibody titer in most patients.1

Complement: Pemphigus antibody fixes components of complement to the surface of epidermal cells. Antibody binding may activate complement with the release of inflammatory mediators and recruitment of activated T cells.

Frequency

United States

PV is uncommon, and the exact incidence and prevalence depends on the population studied.

International
PV has been reported to occur worldwide. PV incidence varies from 0.5-3.2 cases per 100,000. PV incidence is increased in patients of Ashkenazi Jewish descent and those of Mediterranean origin.

Mortality/Morbidity

PV is a potentially life-threatening autoimmune mucocutaneous disease with a mortality rate of approximately 5-15%. Complications secondary to the use of high-dose corticosteroids contribute to the mortality rate. Morbidity and mortality are related to the extent of disease, the maximum dose of systemic steroids required to induce remission, and the presence of other diseases. Prognosis is worse in patients with extensive disease and in older patients.

- PV involves mucosa in 50-70% of patients. This may limit oral intake secondary to dysphagia. Blistering and erosions secondary to the rupture of blisters may be painful and limit the patient's daily activities.
- Patients with PV typically heal without scarring unless the disease is complicated by severe secondary infection.

Race

PV affects all races. The prevalence of PV is high in regions where the Jewish population is predominant. For example, in Jerusalem, the prevalence of PV was estimated at 1.6 cases per 100,000 population; in Connecticut, the prevalence was 0.42 cases per 100,000 population. Incidence of PV in Tunisia is estimated at 2.5 cases per million population per year (3.9 in women, 1.2 in men), while in France, the incidence is 1.3 cases per million population per year (no significant difference between men and women). In Finland, where few people of Jewish or Mediterranean origin live, the prevalence is low, at 0.76 cases per million population.

Sex

Male-to-female ratio is approximately equal. In adolescence, girls are more likely to be affected than boys.

Age

Mean age of onset is approximately 50-60 years; however, the range is broad, and disease onset in older individuals and in children has been described. Patients are younger at presentation in India than in Western countries.

Clinical History

- Mucous membranes: PV presents with oral lesions in 50-70% of patients, and almost all patients have mucosal lesions. Mucosal lesions may be the sole sign for an average of 5 months before skin lesions develop, or they may be the sole manifestation of the disease.
- Skin: Most patients develop cutaneous lesions. The primary lesion of PV is a flaccid blister, which usually arises on normal-appearing skin but may be found on erythematous skin. New blisters usually are flaccid or become flaccid quickly. Affected skin often is painful but rarely pruritic.
- Drug-induced PV: Drugs reported most significantly in association with PV include penicillamine, captopril, and other thiol-containing compounds. Rifampin and emotional stress have recently been reported as triggers for PV.

Physical

Mucous membranes typically are affected first in PV. Mucosal lesions may precede cutaneous lesions by months. Patients with mucosal lesions may present to dentists, oral surgeons, or gynecologists.
Mucous membranes

- Intact bullae are rare in the mouth. More commonly, patients have ill-defined, irregularly shaped, gingival, buccal or palatine erosions, which are painful and slow to heal. The erosions extend peripherally with shedding of the epithelium.

- The mucous membranes most often affected are those of the oral cavity, which is involved in almost all patients with PV and sometimes is the only area involved. Erosions may be seen on any part of the oral cavity. Erosions can be scattered and often extensive. Erosions may spread to involve the larynx with subsequent hoarseness. The patient often is unable to eat or drink adequately because the erosions are so uncomfortable.

- Other mucosal surfaces may be involved, including the conjunctiva, esophagus, labia, vagina, cervix, penis, urethra, and anus.

Skin: The primary lesion of PV is a flaccid blister filled with clear fluid that arises on normal skin or on an erythematous base. The blisters are fragile; therefore, intact blisters may be sparse. The contents soon become turbid, or the blisters rupture producing painful erosions, which is the most common skin presentation. Erosions often are large because of their tendency to extend peripherally with the shedding of the epithelium.
Early, small blister filled with clear fluid arises on healthy skin.

Flaccid blister filled with clear fluid arises on healthy skin.
Vegetating PV: Ordinary PV erosions may develop vegetation. Lesions in skin folds readily form vegetating granulations. In some patients, erosions tend to develop excessive granulation tissue and crusting, and these patients display more vegetating lesions. This type of lesion tends to occur more frequently in intertriginous areas and on the scalp or face. The vegetating type of response can be more resistant to therapy and can remain in one place for long periods of time.
An erosion.

- Nails: Acute paronychia, subungual hematomas, and nail dystrophies have been reported with PV.
- Pemphigus in pregnancy: Occurrence in pregnancy is rare. When present, maternal autoantibodies may cross the placenta, resulting in neonatal pemphigus. Neonatal pemphigus is transient and improves with clearance of maternal autoantibodies.
- Nikolsky sign: In patients with active blistering, firm sliding pressure with a finger separates normal-appearing epidermis, producing an erosion. This sign is not specific for PV and is found in other active blistering diseases.
- Asboe-Hansen sign: Lateral pressure on the edge of a blister may spread the blister into clinically unaffected skin.

**Causes**

The cause of PV remains unknown; however, several potentially relevant factors have been identified.

- Genetic factors: Predisposition to pemphigus is linked to genetic factors. Certain major histocompatibility complex (MHC) class II molecules, in particular alleles of human leukocyte antigen DR4 (DRB1*0402) and human leukocyte antigen DRw6 (DQB1*0503), are common in patients with PV.
- Age: Peak age of onset is from 50-60 years. Infants with neonatal pemphigus remit with clearance of maternal autoantibodies. The disease may present in childhood or in older persons.
- Disease association: Pemphigus occurs in patients with other autoimmune diseases, particularly myasthenia gravis and thymoma.

**Differential Diagnoses**

- Bullous Pemphigoid
- Dermatitis Herpetiformis
- Erythema Multiforme
- Familial Benign Pemphigus (Hailey-Hailey Disease)
- Linear IgA Dermatosis
- Pemphigus Erythematosus
- Pemphigus Foliaceus
- Pemphigus Herpetiformis
- Pemphigus, Drug-Induced
- Pemphigus, IgA
- Pemphigus, Paraneoplastic
- Pemphigus Vulgaris

**Other Problems to Be Considered**

- Erythema multiforme
- Aphthous ulcers
- Herpetic stomatitis
- Bullous lichen planus

**Workup**

**Laboratory Studies**

- To establish a diagnosis of pemphigus vulgaris (PV), perform the following tests:
  - Histopathology from the edge of a blister
  - Direct immunofluorescence (DIF) on normal-appearing perilesional skin
  - Indirect immunofluorescence (IDIF) using the patient's serum if DIF is positive. The preferred substrate for IDIF is monkey esophagus or salt-split normal human skin substrate.
DIF demonstrates in vivo deposits of antibodies and other immunoreactants, such as complement. DIF usually shows IgG deposited on the surface of the keratinocytes in and around lesions. IgG1 and IgG4 are the most common subclasses. Complement components such as C3 and immunoglobulin M are present less frequently than IgG. DIF shows intercellular deposition throughout the epidermis. This pattern of immunoreactants is not specific for PV and may be seen in pemphigus vegetans, pemphigus foliaceus, and pemphigus erythematosus. The best location for DIF is normal perilesional skin. When DIF is performed on lesional skin, false-positive results can be observed.
Direct immunofluorescence showing intercellular immunoglobulin G throughout the epidermis of a patient with pemphigus vulgaris.
Skin biopsy specimens placed in transport media may yield false-negative results; therefore, fresh tissue is the preferred substrate for DIF studies. In the patient’s serum, IDIF demonstrates the presence of circulating IgG autoantibodies that bind to epidermis. Circulating intercellular antibodies are detected using IDIF in 80-90% of patients with PV. The titer of circulating antibody correlates with disease course.**

### Histologic Findings

Histopathology demonstrates an intradermal blister. The earliest changes consist of intercellular edema with loss of intercellular attachments in the basal layer. Suprabasal epidermal cells separate from the basal cells to form clefts and blisters. Basal cells are separated from one another and stand like a row of tombstones on the floor of the blister, but they remain attached to the basement membrane. Blister cells contain some acantholytic cells. Histopathology can help differentiate PV from pemphigus foliaceous, which demonstrates a more superficial epidermal cleavage.

Tzanck preparation is a smear taken from the base of a blister or an oral erosion that contains acantholytic cells. Blistering is preceded by eosinophilic spongiosis in some patients. The superficial dermis has a mild, superficial, mixed inflammatory infiltrate, which includes some eosinophils.

### Treatment

#### Medical Care

The aim of treatment in pemphigus vulgaris (PV) is the same as in other autoimmune bullous diseases, which is to decrease blister formation, promote healing of blisters and erosions, and determine the minimal dose of medication necessary to control the disease process. Therapy must be tailored for each patient, taking into account preexisting and coexisting conditions. Patients may continue to experience mild disease activity while under optimal treatment.
Erosions and healing areas on the back.
Corticosteroids have improved overall mortality, but now much of the mortality and morbidity in these patients relates to the adverse effects of therapy. Whether massive doses of steroids have any advantage over doses of 1 mg/kg/d is unclear. Immunosuppressive drugs are steroid sparing and should be considered early in the course of the disease. Epidermal growth factor may speed healing of localized lesions. Amagai et al reported on the successful use of intravenous immunoglobulin in pemphigus patients who did not fully respond to systemic steroids.  

**Consultations**

Management of patients with PV requires coordination of care between the dermatologist and the patient's primary care physician.

- An ophthalmologist should evaluate patients with suspected ocular involvement and those requiring prolonged high-dose steroids.
○ Patients with oral disease may require a dentist and/or an otolaryngologist for evaluation and care.
○ Patients on systemic steroids should maintain adequate vitamin D and calcium intake through diet and supplements. Patients with a history of renal calculi should not receive calcium carbonate.
○ Patients receiving long-term systemic corticosteroids should be evaluated by a rheumatologist within the first 30 days of treatment for osteoporosis risk assessment and consideration of a bisphosphonate for prophylaxis against osteoporosis.

**Diet**

No dietary restrictions exist, but patients with oral disease may benefit from avoiding foods, such as spicy foods, tomatoes, orange juice, and hard foods that may traumatize the oral epithelium mechanically, such as nuts, chips, and hard vegetables and fruit.

**Activity**

○ Advise patients to minimize activities that traumatize the skin and that may precipitate blistering, such as contact sports. Nontraumatic exercises, such as swimming, may be helpful.
○ Dental plates, dental bridges, or contact lenses may precipitate or exacerbate mucosal disease.

**Medication**

The aim of treatment is to reduce inflammatory response and autoantibody production. While target-specific therapy is not available, non-target-specific treatments currently are used. The most commonly used medications are corticosteroids.

The introduction of corticosteroids has reduced mortality greatly, but significant morbidity remains. Immunosuppressants should be considered early in the course of disease, as steroid-sparing agents. Mycophenolate mofetil and azathioprine are the usual first-line agents. Rituximab and intravenous immunoglobulin have also proved useful alone or in combination. Cyclophosphamide is used for refractory disease. The role of biologic agents is being investigated. Each of these agents should be prescribed and monitored by physicians familiar with them. Wound care of erosions includes daily gentle cleaning, application of topical agents to promote wound healing, and use of nonadhesive dressings. The goal of wound care is to promote healing, minimize trauma to the surrounding skin, and diminish scarring.

**Anti-inflammatory agents**

Inhibit the inflammatory process by inhibiting specific cytokine production.

**Prednisone (Deltasone, Meticorten, Orasone, Sterapred)**

May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. Stabilizes lysosomal membranes and also suppresses lymphocytes and antibody production. For treating PV, administered PO and used alone or in combination with topical or intralesional steroids or in conjunction with other immunosuppressives.

In pediatric patients, disease management with this medication in consultation with the patient's pediatrician is advised.

**Dosing**

**Adult**
1-1.5 mg/kg/d PO initial every am or in divided doses; titrate dose to clinical response; 0.5-2 mg/kg/d; taper as condition improves; single morning dose is safer for long-term use, but divided doses have more anti-inflammatory effect

**Pediatric**

Administer as in adults

**Interactions**

Coadministration with estrogens may decrease prednisone clearance; when used with digoxin, digitalis toxicity secondary to hypokalemia may increase; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics

**Contraindications**

Documented hypersensitivity; viral infection, peptic ulcer disease, hepatic dysfunction, connective tissue infections, and fungal or tubercular skin infections; GI disease

**Precautions**

**Pregnancy**

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

**Precautions**

Abrupt discontinuation of glucocorticoids may cause adrenal crisis; peptic ulcer disease, hypokalemia, hyperglycemia, osteonecrosis, myopathy, osteoporosis, edema, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur; qod therapy does not prevent bone loss

**Immunosuppressive agents**

Useful adjuvants in patients with PV with generalized disease unresponsive to steroids and/or other anti-inflammatory agents or in patients unable to tolerate prednisone.

**Azathioprine (Imuran)**

Antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. May decrease proliferation of immune cells, which results in lower autoimmune activity. In conjunction with prednisone, it is more effective than prednisone alone. May be an effective monotherapy in mild cases, although the therapeutic effect is delayed 3-5 wk. Consider withdrawal if no improvement within 3 mo.

**Dosing**

**Adult**
1 mg/kg/d qd/bid (empiric) or based on TPMT level (see Precautions); increase dose by 0.5 mg/kg/d after 6-8 wk if necessary; increase q4wk; 2 mg/kg/d maximum dose for most dermatologic purposes

**Pediatric**

Not established

**Interactions**

Allopurinol increases risk of pancytopenia; captopril/ACE inhibitors may increase risk of anemia and leukopenia; warfarin dose may need to be increased; pancuronium may need to be increase to achieve adequate paralysis; live virus vaccines, co-trimoxazole may increase risk of hematologic toxicity; rifampicin may cause transplant rejection; clozapine may increase risk of agranulocytosis

**Contraindications**

Absolute: Allergy to azathioprine, pregnancy or attempting pregnancy, clinically significant active infection

Relative: Concurrent use of allopurinol, prior treatment with alkylating agents (cyclophosphamide, chlorambucil, melphalan, others) because of high risk of neoplasia; pediatric patients (safety and efficacy in pediatric population not established)

**Precautions**

**Pregnancy**

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

**Precautions**

TPMT testing is not entirely reliable but it involves testing activity of TPMT activity in RBCs, which correlates with systemic TPMT activity; functional enzyme test has been shown to have variability between test sites and the kits may contain varying amounts of enzyme inhibitor; starting at low doses, monitoring for pancytopenia, then increasing dose is an alternative; if clinical response is not good, patient may be homozygote for high activity and may need an increased dose; Wolverton Comprehensive Dermatologic Drug Therapy; other references recommend checking before treatment in all patients

TPMT <5 U: No treatment with azathioprine
TPMT 5-13.7 U: Dose not to exceed 0.5 mg/kg
TPMT 13.7-19 U: Dose not to exceed 1.5 mg/kg
TPMT >19 U: Dose not to exceed 2.5 mg/kg

**Follow-up**

**Complications**

- Secondary infection, which may be either systemic or localized to the skin, may occur because of the use of immunosuppressants and the presence of multiple erosions. Cutaneous infection delays wound healing and increases the risk of scarring.
- Malignancies resulting from immunosuppressants have been reported.
- Growth retardation has been reported in children taking systemic corticosteroids and immunosuppressants.
- Bone marrow suppression has been reported in patients receiving immunosuppressants. Increased incidence is reported of leukemia and lymphoma in patients receiving prolonged immunosuppression.
Impaired immune responsiveness caused by corticosteroids and other immunosuppressive drugs may result in the rapid spread of infection. Corticosteroids suppress clinical signs of infection and may allow diseases such as septicemia or tuberculosis to reach an advanced stage before diagnosis. Osteoporosis may occur following the use of systemic corticosteroids. Adrenal insufficiency has been reported following prolonged use of glucocorticoids.

**Prognosis**

- The severity and natural history of pemphigus vulgaris (PV) are variable, but before the advent of steroids, most patients with PV died. Treatment with systemic steroids has reduced the mortality rate to 5-15%.
- Most deaths occur during the first few years of disease, and if the patient survives 5 years, the prognosis is good. Early disease probably is easier to control than widespread disease, and mortality may be higher if therapy is delayed.
- Morbidity and mortality are related to the extent of disease, the maximum dose of prednisolone required to induce remission, and the presence of other diseases. The outlook is worse in older patients and in patients with extensive disease.

**Patient Education**

- Minimize trauma to the skin because the patient's skin is fragile both from the disease and from the use of topical and systemic steroids.
- The patient's understanding of the disease and education is important because of the chronic nature of this disorder.
- Educate patients regarding their medications. They should know about dose, adverse effects, and symptoms of toxicity so they can report adverse effects to the physician.
- Educate patients about appropriate wound care.

**Miscellaneous**

**Medicolegal Pitfalls**

- Failure to secure the correct diagnosis using a compatible history and physical and appropriate testing. Routine histology and immunofluorescence should be performed to confirm the diagnosis and prior to treatment.
- Failure to explain adverse effects of treatment to patients on systemic therapy. Patients must be monitored appropriately for adverse effects, toxicity, and response to treatment.

**Special Concerns**

- An accurate diagnosis is important before starting the treatment. Pemphigus vulgaris (PV) shares some common features with other autoimmune blistering diseases, which sometimes makes the diagnosis difficult. Criteria for diagnosis include the following:
  - Compatible clinical picture
  - Intraepidermal blistering disease confirmed by histopathology
  - Intercellular immunofluorescence throughout the epidermis of immunoglobulin and complement components confirmed by DIF and IDIF
- Physicians should educate patients about the disease, adverse effects, risks, drug interactions, and contraindications of the medications.
- Therapeutic regimen is chosen for each individual patient after assessing the risk and benefits for each medication.

**Multimedia**
Media file 1: Early, small blister filled with clear fluid arises on healthy skin.

Media file 2: Flaccid blister filled with clear fluid arises on healthy skin.
Media file 3: An erosion.
Media file 4: Erosions and healing areas on the back.
Media file 5: Healing areas on the chest and abdomen.
Media file 6: Direct immunofluorescence showing intercellular immunoglobulin G throughout the epidermis of a patient with pemphigus vulgaris.
References


